Pre-Operative PARPi and Irradiation (POPI) in Women With an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
Latest Information Update: 24 May 2024
Price :
$35 *
At a glance
- Drugs Veliparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
- Focus Adverse reactions
- 21 May 2024 Status changed from suspended to completed.
- 20 Aug 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 20 Aug 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.